Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.76 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.76 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.76 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8134421 | 0.87 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL9734713 | 0.81 | GABRA1 (0.54) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL357603 | 0.79 | GABRA1 (0.48) | GABRA1GABRG2GABRB3GABRB2CA1 | |
| SCHEMBL5823486 | 0.79 | GABRA1 (0.52) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL3865790 | 0.79 | GABRA1 (0.52) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL6215211 | 0.79 | GABRA1 (0.52) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL15397424 | 0.79 | GABRA1 (0.76) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL18629974 | 0.78 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL15112989 | 0.78 | GABRA1 (0.73) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL327307 | 0.78 | GABRA1 (0.73) | GABRA1GABRG2GABRB3GABRB2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2023-10-31 | — | — | US | disclosed |
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2020-08-27 | — | — | US | disclosed |
| EP-1073657-B1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRAZENECA AB (SE) | 2005-12-07 | — | — | EP | disclosed |
| US-6313137-B1 | FOR THERAPY AND PROPHYLAXIS OF GASTROINTESTINAL INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2001-11-06 | — | — | US | disclosed |
| EP-1073657-A1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | AstraZeneca AB (SE) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055706-A9 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRA AB (SE) | 2000-03-16 | — | — | WO | disclosed |
| WO-1999055706-A1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRAZENECA AB (SE) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | GABRA1 395/4885GABRG2 1015/4885GABRB3 382/4885 |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | SMN1; SMN2, SNCA, HTT | GABRA1 395/4885GABRG2 1015/4885GABRB3 382/4885 |
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | GABRA1 395/4885GABRG2 1015/4885GABRB3 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.